Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > October 5, 2022
Daily News
October 5, 2022
- JMA Chuikyo Rep Urges Savings from Off-Year Drug Price Cuts to Be Allocated to Medical Fees
October 5, 2022
- Shionogi, UN Agency Tie Up for Generic Distribution of COVID Pill in Low-Middle-Income Nations
October 5, 2022
- Astellas/Pantherna Expand mRNA-Based Regenerative Medicine Collab to Add New Target Organ
October 5, 2022
- Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
- 3rd COVID-19 Shot for Kids Aged 5-11 Effective as Booster: Infectious Diseases Association
October 5, 2022
- Takeda to Discontinue Natpar/Natpara Production at End of 2024
October 5, 2022
- Antimicrobial Use in 2021 Down 31.5% from 2013: Expert
October 5, 2022
- Japan Panel OKs Inclusion of Silgard 9 into National Immunization Program
October 5, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…